A novel embolization-on-a-chip model allows testing various embolic agent classes to treat liver cancer
Peer-Reviewed Publication
Updates every hour. Last Updated: 9-Sep-2025 23:11 ET (10-Sep-2025 03:11 GMT/UTC)
Los Angeles, CA – September 3, 2025 - Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate vessel remodeling and cell death in response to embolic agents. This novel platform reflects the microenvironment of liver tumors, particularly a functional and perfusable microvasculature that can be embolized. This powerful in vitro tool aligns with the National Institutes of Health (NIH) efforts to reduce animal testing and promote alternative methods, including microfluidic devices that mimic human organs.
A research team introduces the In-Media Plant PET Root Imaging System (IMP2RIS), a novel tool that enables real-time, non-invasive, three-dimensional imaging of symbiotic nitrogen fixation (SNF) in soybean roots grown in soil-like media.
A research team led by Professor Jason Kyungha Sa from the Department of Biomedical Informatics at Korea University College of Medicine has identified a novel therapeutic target for recurrent meningioma through precision genomic analysis.
Scientists know that both gray seals and harbor seals can contract influenza. But, generally, only harbor seals get sick and may die from the virus.
This perplexing phenomenon led Milton Levin ‘04 Ph.D., associate research professor of pathobiology and veterinary science in the College of Agriculture, Health and Natural Resources (CAHNR), and his collaborators to investigate if a difference in a piece of the immune system called cytokines could be responsible for this difference.